Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect

NCT01344967 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01344967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01344967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect
Lead sponsor
University Health Network, Toronto
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 2009
Completion date
December 31, 2011
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer with bone involvement